Provided by Tiger Trade Technology Pte. Ltd.

Foghorn Therapeutics Inc.

2.07
+0.05002.48%
Volume:69.34K
Turnover:141.25K
Market Cap:122.93M
PE:-2.12
High:2.10
Open:2.02
Low:2.00
Close:2.02
52wk High:7.61
52wk Low:1.79
Shares:59.39M
Float Shares:28.08M
Volume Ratio:2.64
T/O Rate:0.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9742
EPS(LYR):-1.1800
ROE:-470.38%
ROA:-19.92%
PB:-1.52
PE(LYR):-1.75

Loading ...

Foghorn Therapeutics Shares Fall After Wedbush Downgrade

MT Newswires Live
·
Oct 03

Correction: Top Midday Decliners

MT Newswires Live
·
Oct 02

Foghorn Therapeutics (FHTX) Receives a Buy from Guggenheim

TIPRANKS
·
Oct 02

Foghorn Therapeutics downgraded to Neutral from Outperform at Wedbush

TIPRANKS
·
Oct 02

Foghorn Therapeutics Inc. : H.c. Wainwright Cuts Target Price to $5 from $13

THOMSON REUTERS
·
Oct 02

TD Cowen Downgrades Foghorn Therapeutics to Hold From Buy

MT Newswires Live
·
Oct 02

Foghorn Therapeutics Cut to Neutral from Buy by BTIG

Dow Jones
·
Oct 02

Foghorn Therapeutics Inc. : Btig Cuts to Nutral from Buy

THOMSON REUTERS
·
Oct 02

Sector Update: Healthcare

MT Newswires Live
·
Oct 02

Foghorn Therapeutics downgraded to Market Perform from Outperform at Citizens

TIPRANKS
·
Oct 02

US Stocks on the MOVE-Cardinal Health, nVent, Acuity

Reuters
·
Oct 02

Foghorn Therapeutics: Buy Rating Maintained as Strategy Refocuses on EP300 Degrader; Price Target Cut to $5 After SMARCA2 Program Removal

TIPRANKS
·
Oct 02

Foghorn Therapeutics price target lowered to $5 from $12 at Stifel

TIPRANKS
·
Oct 02

Foghorn Stock Craters as Lilly Scraps Cancer Deal, Forcing Nearly Half of Staff Layoffs

Dow Jones
·
Oct 01

Eli Lilly (LLY) Ends Cancer Development Deal with Foghorn Therapeutics

TIPRANKS
·
Oct 01

Foghorn Therapeutics Shares Fall 45% Premarket After Co Scraps Development of Cancer Drug with Eli Lilly, to Cut 40% of Workforce

THOMSON REUTERS
·
Oct 01

Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials with Ely Lilly

Dow Jones
·
Oct 01

Foghorn Therapeutics Cuts Workforce About 40% in Reorganization to Extend Cash Runway into H2 2029

Reuters
·
Oct 01

Foghorn Therapeutics - Expects to Have About 65 Full-Time Employees After Reduction - SEC Filing

THOMSON REUTERS
·
Oct 01

Foghorn Therapeutics - Estimates $2.30 Mln Charges for Workforce Reduction in Q4 2026 - SEC Filing

THOMSON REUTERS
·
Oct 01